Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TTK | P33981 | 1/20 | 0.45 |
| ▸ | TNK2 | Q07912 | 1/20 | 0.44 |
| ▸ | MAPKAPK5 | Q8IW41 | 4/20 | 0.44 |
| ▸ | SYK | P43405 | 1/20 | 0.43 |
| ▸ | BTK | Q06187 | 1/20 | 0.42 |
| ▸ | AURKA | O14965 | 2/20 | 0.41 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.41 |
| ▸ | TTBK1 | Q5TCY1 | 2/20 | 0.41 |
| ▸ | TTBK2 | Q6IQ55 | 2/20 | 0.41 |
| ▸ | EED | O75530 | 1/20 | 0.40 |
| ▸ | PTK6 | Q13882 | 1/20 | 0.40 |
| ▸ | FYN | P06241 | 1/20 | 0.40 |
| ▸ | KDM1A | O60341 | 1/20 | 0.40 |
| ▸ | ABL1 | P00519 | 1/20 | 0.39 |
| ▸ | BCR | P11274 | 1/20 | 0.39 |
| ▸ | ERN1 | O75460 | 1/20 | 0.38 |
| ▸ | PRKD1 | Q15139 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3469679 | 0.84 | PRKD1 (0.40) | TTKTNK2MAPKAPK5SYKEED | |
| SCHEMBL3471563 | 0.81 | ERN1 (0.46) | TTKMAPKAPK5SYKTTBK1TTBK2 | |
| SCHEMBL3469745 | 0.81 | ABL1 (0.51) | TTKMAPKAPK5SYKAURKAAURKB | |
| SCHEMBL3470478 | 0.79 | MAPKAPK5 (0.43) | TTKMAPKAPK5SYKAURKAAURKB | |
| SCHEMBL5618954 | 0.79 | FLT3 (0.51) | TTKMAPKAPK5SYKEEDFYN | |
| SCHEMBL5573319 | 0.76 | MAPKAPK5 (0.75) | MAPKAPK5SYKBTKPTK6FYN | |
| SCHEMBL3470512 | 0.76 | SYK (0.49) | MAPKAPK5SYKFYNPRKD1 | |
| SCHEMBL1674087 | 0.76 | MAPKAPK5 (0.60) | MAPKAPK5SYKAURKAAURKBPTK6 | |
| SCHEMBL8246761 | 0.76 | AURKA (0.64) | TTKTNK2MAPKAPK5BTKAURKA | |
| SCHEMBL3469690 | 0.76 | PRKD1 (0.44) | TTKMAPKAPK5SYKEEDPRKD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120302565-A1 | KINASE INHIBITORS FOR PREVENTING OR TREATING PATHOGEN INFECTION AND METHOD OF USE THEREOF | M.D. ANDERSON CANCER CENTER (US) | 2012-11-29 | — | — | US | disclosed |
| US-20120302565-A1 | KINASE INHIBITORS FOR PREVENTING OR TREATING PATHOGEN INFECTION AND METHOD OF USE THEREOF | M.D. ANDERSON CANCER CENTER (US) | 2012-11-29 | — | — | US | disclosed |
| US-8268809-B2 | Kinase inhibitors for preventing or treating pathogen infection and method of use thereof | EMORY UNIVERSITY (US) | 2012-09-18 | — | — | US | disclosed |
| US-8268809-B2 | Kinase inhibitors for preventing or treating pathogen infection and method of use thereof | EMORY UNIVERSITY (US) | 2012-09-18 | — | — | US | disclosed |
| EP-2471529-A2 | Kinase Inhibitors for Preventing or Treating Pathogen Infection and Method of Use Thereof | Emory University (US) | 2012-07-04 | — | — | EP | disclosed |
| EP-2364702-A2 | Kinase inhibitors for preventing or treating pathogen infection and method of use thereof | Emory University (US) | 2011-09-14 | — | — | EP | disclosed |
| US-20100249122-A1 | Kinase Inhibitors for Preventing or Treating Pathogen Infection and Method of Use Thereof | EMORY UNIVERSITY (US) | 2010-09-30 | — | — | US | disclosed |
| US-20100249122-A1 | Kinase Inhibitors for Preventing or Treating Pathogen Infection and Method of Use Thereof | EMORY UNIVERSITY (US) | 2010-09-30 | — | — | US | disclosed |
| US-20100144743-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF TYROSINE KINASES | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2010-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100249122-A1 | Kinase Inhibitors for Preventing or Treating Pathogen Infection and Method of Use Thereof | MAP3K1, MAP3K2, MAP3K6 | TTK 147/4885TNK2 137/4885MAPKAPK5 46/4885 |
| US-20100144743-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF TYROSINE KINASES | ABL1, LCK, SRC | TTK 160/4885TNK2 53/4885MAPKAPK5 273/4885 |
| US-20120302565-A1 | KINASE INHIBITORS FOR PREVENTING OR TREATING PATHOGEN INFECTION AND METHOD OF USE THEREOF | MAP3K1, MAP3K2, MAP3K6 | TTK 147/4885TNK2 137/4885MAPKAPK5 46/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.